SCHEMBL26758014

SCHEMBL26758014

Nc1ccc([N+](=O)[O-])cc1C(=O)Nc1ccncc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.76
MAPK1 P28482 4/20 0.76
CYP3A4 P08684 2/20 0.76
PPARG P37231 2/20 0.76
ALOX15 P16050 1/20 0.76
PPARA Q07869 1/20 0.76
TDP1 Q9NUW8 2/20 0.67
KMT2A Q03164 6/20 0.66
ALDH1A1 P00352 3/20 0.66
POLB P06746 4/20 0.59
MAPT P10636 4/20 0.59
MITF O75030 1/20 0.59
MEN1 O00255 4/20 0.58
GAA P10253 1/20 0.58
HTT P42858 1/20 0.58
NCOA1 Q15788 1/20 0.58
NCOA3 Q9Y6Q9 1/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 1/20 0.58
LMNA P02545 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29369085 0.86 SMN1; SMN2 (1.00) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL2128178 0.86 SMN1; SMN2 (1.00) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL6811505 0.85 KMT2A (0.74) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
Hydrochloric Acid SCHEMBL7125284 0.85 SMN1; SMN2 (0.97) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL8122501 0.84 SMN1; SMN2 (0.70) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL26758011 0.84 SMN1; SMN2 (0.74) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL27886556 0.82 SMN1; SMN2 (0.90) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL7127082 0.80 SMN1; SMN2 (0.86) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL9954063 0.79 JAK2 (0.54) SMN1; SMN2MAPK1CYP3A4PPARGALOX15
SCHEMBL7122859 0.79 MAPK1 (0.86) SMN1; SMN2MAPK1CYP3A4PPARGALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
EP-4171569-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF Council of Scientific & Industrial Research (IN) 2023-05-03 EP disclosed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC SMN1; SMN2 3760/4885MAPK1 2282/4885CYP3A4 433/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 SMN1; SMN2 3400/4885MAPK1 2409/4885CYP3A4 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.